A new cancer drug under development could begin phase 1 testing in humans next year after it obtained good results in treating eight types of cancers in animal tests, the National Health Research Institutes (NHRI) announced yesterday.
Hsieh Hsing-pang (謝興邦), a researcher at the NHRI’s Institute of Biotechnology and Pharmaceutical Research (IBPR), said at a media briefing that 40 late-stage cancer patients who have not been helped by any available treatment, but are still in decent physical condition, are to be recruited for phase 1 clinical trials next year.
The new drug, known as DBPR144, is a small molecule known as a multi-target kinase inhibitor, Hsieh said.
Photo: CNA
A kinase is an enzyme that controls important cell functions, and it can be active in the growth of some types of cancer cells.
The eight types of cancers against which it showed success through in vivo studies in animals were pancreatic, oral, gastric, liver, bladder, prostate and colorectal cancer, as well as acute myeloid leukemia, Hsieh said.
“Because it is particularly effective in gastroenterology-related cancers, we are likely to first target patients with pancreatic, liver, bladder and gastric cancer in the initial clinical trial,” he said.
Multi-target drugs, which take aim at several targets rather than more common medications that only target a single biological substance, more effectively inhibit cancer cell proliferation and overcome drug resistance, he said.
During the phase 1 trial, the volunteers are to be given DBPR114 once a week to determine safe dosages of the drug, Hsieh said.
Chen Chiu-heng (陳丘泓), general manager of Launxp Biomedical Co, which will be responsible for manufacturing the drug, said cancer patients from Taiwan and Australia are to be recruited to take part in the initial trial, which is expected to take two years.
Phase 2 and phase 3 trials, which should each take two to three years, will focus on cancers that responded promisingly to the drug in phase 1.
At least six years will be needed to complete human trials, Chen said.
“This novel, multi-targeted agent is our new hope for treating cancer patients,” IBPR Director Chang Jang-yang (張俊彥) said.
Cancer has been the top cause of death in Taiwan for 41 years, he said, and the five-year survival rates among patients with major types of cancer remained low, especially the 5 percent rate for people with pancreatic cancer.
FUKUOKA SITUATION: Japanese media reported that the pathogen is expected to be identified by the summer, while the CDC downplayed the idea that it was hMPV A “mysterious cold-like illness” reported in Japan’s Fukuoka Prefecture does not seem to be a new disease, but Japanese authorities have been asked about the situation, the Centers for Disease Control (CDC) said yesterday. The Fukuoka Prefectural Medical Association on Wednesday told a news conference that a “mystery cold” that has become a hot topic on social media is “highly likely to be caused by some kind of viral infection,” Japan’s KBC News reported. “Many people are experiencing symptoms starting with a sore throat, followed by a runny nose, phlegm and a severe cough,” KBC News reported, citing association officials. Health authorities are
Nvidia Corp CEO Jensen Huang (黃仁勳) arrived in Taiwan yesterday ahead of upcoming AI and technology events, saying he plans to meet with clients and Taiwan Semiconductor Manufacturing Co Chairman C.C. Wei (魏哲家) during his visit. After landing at Taipei Songshan Airport, Huang posed for photos with fans and handed out Yakult drinks to reporters and supporters waiting at the scene, saying he has “a lot to do” during the trip. Asked about reports that Nvidia’s planned headquarters site in Taipei’s Beitou Shilin Technology Park could break ground on May 27, Huang said that if the company holds an event, he would
The Ministry of Finance this afternoon announced the winning numbers for the March-April uniform invoice lottery. The winning number for the NT$10 million (US$318,060) special prize is 19531471, and the winning number for the NT$2 million grand prize is 85941329. Three numbers were drawn for the NT$200,000 first prize: 07225810, 20231230 and 83518781. Those with receipts matching the last seven digits of any of the first-prize numbers will win the NT$40,000 second prize, while those matching the last six digits will win the NT$10,000 third prize. Those whose receipts match the last five digits of the first-prize numbers can claim the NT$4,000 fourth prize,
Taiwan Travelogue (臺灣漫遊錄), which earlier this week became the first Taiwanese novel to win the International Booker Prize, is to be adapted into a television series through a Taiwan-Japan coproduction, producer Chang Chen-yu (張辰漁) said yesterday. Chang, a producer at World Softest Production Film Co, wrote on Facebook that the company had been searching for projects with international appeal that retain a strong Taiwanese identity after colleagues and Japanese partners strongly recommended the novel. After reading the book, Chang said he immediately decided to pursue the screen rights. “A great story has the power to transcend time and borders, and connect countless people,”
RSS